Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

BDNF / Neuroplasticity Pathway

Also: Brain-Derived Neurotrophic Factor · id BDNF

Growth factor central to synaptic plasticity and a downstream effector of chronic SSRI treatment. Several botanicals have been investigated for BDNF modulation.

7 drugs act here4 plants reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on BDNF / Neuroplasticity Pathway

These medications have BDNF / Neuroplasticity Pathway among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on BDNF / Neuroplasticity Pathway

Each plant below contains a named compound documented to act on BDNF / Neuroplasticity Pathway. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • Morinda officinalis oligosaccharides (MOO)Oligosaccharide / prebiotic

    Preclinical and clinical studies report that MOO is minimally absorbed systemically; proposed mechanism involves gut microbiota modulation of the tryptophan → 5-HTP → serotonin pathway, with downstream increases in central 5-HT and reported BDNF upregulation. MOO is an orally approved drug in China for depressive disorder.

  • Fructooligosaccharides (OMO subset of MOO)Fructooligosaccharide / prebiotic

    Rodent model studies investigated OMO effects on the microbiota-gut-brain axis in Alzheimer's disease-like models, with reported increases in BDNF and improvements in cognitive markers; human evidence is not yet established.

  • CrocinCarotenoid glycoside

    Primary mood-active carotenoid; modulates serotonergic signaling and BDNF expression in animal and human models.

  • CrocetinCarotenoid

    Crocin's carotenoid metabolite; antioxidant and BDNF-modulating activity.

  • AsiaticosideTriterpene saponin

    Primary 'wound-healing' compound — stimulates collagen synthesis and angiogenesis at wound site. Basis for venous-insufficiency clinical evidence.

  • Asiatic acidTriterpene acid

    Aglycone form active in CNS; preclinical neurogenic / anti-inflammatory signal.

  • Bacosides A & BTriterpene saponin

    Primary nootropic constituents; BDNF modulation and serotonergic activity contribute to cognitive and mood effects.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.